AstraZeneca Halts Late-Stage Lung Cancer Trial After Volrustomig Fails to Meet Endpoints
The pharmaceutical giant discontinued its eVOLVE-Lung02 Phase III trial following a recommendation from the Independent Data Monitoring Committee that the dual checkpoint inhibitor was unlikely to achieve primary survival goals.
Trial Discontinuation
AstraZeneca disclosed on 17 August 2026 that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a first-line therapy for patients with metastatic non-small cell lung cancer (mNSCLC) whose tumours express PD-L1 at levels below 50% (6-K filing, 2026-08-17).
The decision follows a recommendation from the Independent Data Monitoring Committee (IDMC) after a planned review of trial data. The IDMC concluded that the volrustomig combination "was unlikely to meet either of the dual primary endpoints of progression-free survival (PFS) or overall survival (OS) in the primary analysis population of patients with PD-L1 negative tumours (<1%) versus the comparator arm" (6-K filing, 2026-08-17).
The comparator arm consisted of pembrolizumab plus chemotherapy, representing the current standard of care for this patient population.
Safety Profile
The company reported that "the safety profile of volrustomig plus chemotherapy was consistent with the known profiles of the individual medicines and no new safety signals were identified" (6-K filing, 2026-08-17). AstraZeneca stated it will work with investigators to ensure continuity of care and appropriate follow-up for patients enrolled in the trial.
Trial Design and Scope
The eVOLVE-Lung02 trial was a randomized, open-label, multi-centre global Phase III study that enrolled 895 patients across 25 countries (6-K filing, 2026-08-17). Patients were randomized 1:1 to receive either 750mg intravenous volrustomig with chemotherapy or 200mg pembrolizumab plus chemotherapy.
The dual primary endpoints were progression-free survival and overall survival in patients whose tumours express PD-L1 at levels below 1%, with secondary endpoints including PFS and OS in the intent-to-treat population of patients with PD-L1 expression below 50% (6-K filing, 2026-08-17).
Clinical Context
Lung cancer accounts for nearly one in four cancer deaths globally and is the leading cause of cancer mortality worldwide (6-K filing, 2026-08-17). Non-small cell lung cancer represents 80-85% of all lung cancer cases, with most patients diagnosed at the metastatic stage. Approximately 12% of people with metastatic NSCLC survive five years after diagnosis (6-K filing, 2026-08-17).
Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca, stated: "We initiated the eVOLVE-Lung02 trial aiming to improve the outcomes for patients whose lung cancers have lower PD-L1 expression and a less durable response to current immunotherapy regimens. While we are disappointed, we will learn from this trial and are determined to continue pioneering new medicines from our industry-leading pipeline in our quest to improve outcomes for patients with lung cancer" (6-K filing, 2026-08-17).
Pipeline Impact
Volrustomig is a dual checkpoint inhibitor bispecific antibody designed to deliver coordinated PD-1 and CTLA-4 blockade on the same T cell (6-K filing, 2026-08-17). Despite the setback in non-small cell lung cancer, AstraZeneca confirmed that "the other Phase III volrustomig trials continue as planned in cervical cancer, head and neck squamous cell carcinoma and mesothelioma" (6-K filing, 2026-08-17).
According to MarginX data, AstraZeneca is scheduled to present at the SEB Nordic Large Cap Seminar on 18 August 2026 and the Handelsbanken Life Science Innovation Day on 25 August 2026.
This article was generated by MarginX from the 6-K filing on 2026-08-17. It is not investment advice.